Article Text

Download PDFPDF
Evaluation of keratoconus progression
  1. Mehdi Shajari,
  2. Gernot Steinwender,
  3. Kim Herrmann,
  4. Kate Barbara Kubiak,
  5. Ivana Pavlovic,
  6. Elena Plawetzki,
  7. Ingo Schmack,
  8. Thomas Kohnen
  1. Department of Ophthalmology, Goethe-University, Frankfurt am Main, Germany
  1. Correspondence to Professor Thomas Kohnen, Department of Ophthalmology, Goethe-University, Frankfurt am Main 60590, Germany; kohnen{at}em.uni-frankfurt.de

Footnotes

  • MS and GS contributed equally.

    MS and GS are first authors.

  • Contributors MS contributed towards concept and design, data acquisition, data analysis/interpretation, drafting the manuscript, critical revision, statistical analysis and final approval. GS contributed towards concept and design, data acquisition, data analysis/interpretation, drafting the manuscript, critical revision, statistical analysis and final approval. KH contributed towards data acquisition, drafting the manuscript and final approval. KBK contributed towards data acquisition, data analysis/interpretation and final approval. IP contributed towards data acquisition, data analysis/interpretation and final approval. EP contributed towards data acquisition, drafting the manuscript and final approval. IS contributed towards concept and design, critical revision and final approval. TK contributed towards concept and design, critical revision and final approval.

  • Funding MS: consultant—Oculus, Oertli, Santen, Zeiss; GS: none; KH: none; KBK: none; IP: none; EP: none; IS: none; TK: research funding—Hoya, J&J Vision (Abbott), Novartis (Alcon), Oculentis, Oculus, Schwind, Zeiss; consultant or advisory board—Geuder, J&J Vision (Abbott), Novartis (Alcon), Oculus, Santen, Schwind, STAAR, TearLab, Thea Pharma, Thieme Compliance, Ziemer, Zeiss.

  • Competing interests None declared.

  • Patient consent Not required.

  • Ethics approval Ethik-Kommission des Fachbereichs Medizin der Goethe-Universität Frankfurt am Main.

  • Provenance and peer review Not commissioned; externally peer reviewed.

View Full Text

Statistics from Altmetric.com

Footnotes

  • MS and GS contributed equally.

    MS and GS are first authors.

  • Contributors MS contributed towards concept and design, data acquisition, data analysis/interpretation, drafting the manuscript, critical revision, statistical analysis and final approval. GS contributed towards concept and design, data acquisition, data analysis/interpretation, drafting the manuscript, critical revision, statistical analysis and final approval. KH contributed towards data acquisition, drafting the manuscript and final approval. KBK contributed towards data acquisition, data analysis/interpretation and final approval. IP contributed towards data acquisition, data analysis/interpretation and final approval. EP contributed towards data acquisition, drafting the manuscript and final approval. IS contributed towards concept and design, critical revision and final approval. TK contributed towards concept and design, critical revision and final approval.

  • Funding MS: consultant—Oculus, Oertli, Santen, Zeiss; GS: none; KH: none; KBK: none; IP: none; EP: none; IS: none; TK: research funding—Hoya, J&J Vision (Abbott), Novartis (Alcon), Oculentis, Oculus, Schwind, Zeiss; consultant or advisory board—Geuder, J&J Vision (Abbott), Novartis (Alcon), Oculus, Santen, Schwind, STAAR, TearLab, Thea Pharma, Thieme Compliance, Ziemer, Zeiss.

  • Competing interests None declared.

  • Patient consent Not required.

  • Ethics approval Ethik-Kommission des Fachbereichs Medizin der Goethe-Universität Frankfurt am Main.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • At a glance
    Keith Barton James Chodosh Jost B Jonas